Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

Raymond Schuch, Babar Khalid Khan, Assaf Raz, Jimmy A. Rotolo, Michael Wittekind

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC90) value of
Original languageEnglish (US)
JournalAntimicrobial Agents and Chemotherapy
Issue number7
StatePublished - May 1 2017

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: The work of Raymond Schuch, Babar K. Khan, Jimmy A. Rotolo, and Michael Wittekind was supported by the ContraFect Corporation. The work of Assaf Raz was supported by U.S. Public Health Service grant AI11822 (to Vincent A. Fischetti).


Dive into the research topics of 'Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent'. Together they form a unique fingerprint.

Cite this